Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Earnings Call Transcript
May 26, 2026
Earnings Call Speaker Segments
Ladies and gentlemen, good day, and welcome to the Yatharth Hospital & Trauma Care Services Limited Q4 FY ’26 Earnings Conference Call, hosted by Antique Stock Broking Limited. I'd like to point out that during this call, our discussions will contain certain forward-looking statements — these are predictions, projections, or other estimates regarding future events. Such estimates reflect what management currently expects regarding how the company will perform going forward. Kindly note that these estimates carry several risks and uncertainties, and those could lead the company's actual results to differ materially from what is expressed or implied. <<operator_script>> I'll now turn the conference over to Mr. Sumit Gupta, Senior VP, Institutional Equity Research, Healthcare at Antique Stock Broking Limited. Thank you, and over to you, Mr. Gupta.
Thanks. Hello, and good day to all of you. Antique Stock Broking is glad to have everyone join us for the Q4 and FY ’26 earnings conference call of Yatharth Hospital & Trauma Care Services Limited. Joining us from management today are Mr. Yatharth Tyagi, Whole-Time Director; Mr. Amit Kumar Singh, Group Chief Executive Officer; Mr. Nitin Gupta, President, Finance and Group Chief Operating Officer; Mr. Pankaj Prabhakar, Group Chief Financial Officer; Mr. Ashutosh Kumar Jha, Group Chief Strategy, M&A and Investor Relations; and Mr. Sonu Goyal, Group Chief Finance Controller. I'll now pass the call to Mr. Yatharth Tyagi for his opening remarks. Thank you, and over to you, Yatharth.
Good afternoon, everyone, and welcome to the earnings conference call of Yatharth Hospital & Trauma Care Services Limited, covering the quarter and year that concluded on March 31, 2026. You can find our earnings presentation on the stock exchanges as well as on our website, and we hope you've had a chance to go through it. For Yatharth Hospitals, FY ’26 proved to be an exceptional year of transformation, defined by robust operational execution, strategic expansion into healthcare markets with high potential, faster ramp-up of newly opened facilities, and ongoing enhancement of clinical excellence throughout our network. Consolidated revenue reported by the company for the year came in at roughly INR12,072 million, a strong 36% Y-o-Y rise, and EBITDA grew 30% Y-o-Y, reaching INR2,921 million. On the clinical side, we keep reinforcing our standing as a leading provider of quaternary care via sustained investments in advanced medical technologies, growth of high-end specialties, and the onboarding of well-regarded clinicians. Across the quarter, several notable clinical milestones were delivered by our hospitals, underscoring how deep our tertiary and quaternary care capabilities run. Among these: at Greater Noida Hospital, a complex pan-brachial plexus injury was managed by the neurosurgical team through a precision intercostal nerve-to-nerve musculocutaneous nerve transfer aimed at restoring motor function. In a further case that reinforces our neuroscience leadership, Noida Sector 110 Hospital carried out a navigation-guided awake craniotomy for an intracranial lesion located in the speech area, with continuous intraoperative speech monitoring afterward, which allowed the patient to recover free of neurological speech deficits.
At the Sector 20 Faridabad Facility, which has also become a robust hub for advanced GI interventions, 13 POEM procedures were performed within 2 months of launch, further reinforcing our minimally invasive gastro-sciences capabilities. We are likewise delighted to see expanding recognition of our clinical leadership. At the National Cardiovascular Summit 2025, Dr. Viresh Mahajan was honored as Pediatric Cardiologist of the Year, and Dr. Dhanshuk received the prestigious Desh Ratan Award 2025 for his contribution to pediatrics and neonatology. Dr. Kunal Bahrani was recognized with the Leadership in Neurological Services Award at VOH National Healthcare Awards 2025. Also, Dr. Supradip Ghosh received the Chairman Award for the Lifetime Contribution to Critical Care Medicine from ISCCM Delhi-Noida, Gurugram. Such recognitions highlight the strength of our expanding clinical talent and an ongoing dedication to delivering world-class patient care. Consistent with our cluster-based expansion strategy and after the early success of the Faridabad cluster, we have seeded our next high-potential cluster in the Gurugram market by acquiring an ultra-modern under-construction super specialty hospital in Sector 40, Central Gurugram. The upfront consideration for this project is approximately INR100 crores, together with an additional proposed investment of nearly INR100 crores toward finishing and providing medical infrastructure.
When it becomes operational, that hospital should generate ARPOB above INR50,000, which would place it among the premium healthcare assets in NCR. Its location is strategic — close to IGI Airport and to major residential and corporate catchments — so the facility is well positioned to reinforce our premium healthcare positioning and to grow medical value travel opportunities. Our expectation is that the hospital will be operational by April 2027. In the course of the year, the hospitals we recently opened at New Delhi and Faridabad Sector 20 saw a strong ramp-up. Those facilities scaled up faster than our internal expectations and, within a short period from commencement, have become a meaningful contributor to growth. Combined, these 2 new hospitals accounted for roughly 11% of revenue in quarter four FY ’26 and they keep delivering healthy operating metrics, among them superior ARPOB levels and a favorable payer mix made up largely of cash and TPA patients. We also completed the successful integration of our 250-bedded Agra Hospital, which reinforces our presence along the NCR-Agra healthcare corridor through the Yamuna Expressway. From the effective date of its integration in February 2026, the hospital has shown encouraging traction, reaching a monthly revenue run rate of approximately INR7 crores together with double-digit EBITDA margins, a reflection of strong patient inflows and a healthy operating start. As a demonstration of our clinical excellence, we installed Agra’s first Da Vinci robot and, to date, have successfully completed 50 robotic surgeries.
When it comes to the areas around Agra — in those cities, robotic surgery is something that has been made available for the first time, and Yatharth Group took the initiative by carrying out such a large volume of robotic surgeries in that region. Thanks to strong connectivity with our Noida and Faridabad facilities, we expect the Agra Hospital to develop into a key feeder hub for oncology and other high-value specialties over the medium term. Our Greater Faridabad Hospital, which began operations last year, put up a strong performance and reached profitability during the year, showing our ability to scale new assets efficiently and turn them around. During the year, we further sharpened our focus on international collaborations and global outreach. A key milestone was our association as the exclusive hospital partner for the now operational Noida International Airport at Jewar, which is expected to significantly boost international patient access as well as regional healthcare community and connectivity. As part of our medical value travel initiatives, we carried out multiple international outreach programs across the Middle East and the CIS regions, hosted international delegations, ran OPD initiatives and took part in a strategic healthcare forum, strengthening long-term partnerships and global presence. Looking ahead, we remain focused on scaling up our newly added facilities, driving operational efficiencies, enhancing specialty mix and strengthening our presence across high-growth healthcare markets in North India.
Taking into account the Gurugram site we will open soon plus brownfield additions we have in the works at Noida Extension and Greater Noida, the group now operates more than 3,200 beds in total. We stay confident about hitting our goal of 5,000 beds within the coming 3 years. Since the newer hospitals are posting higher ARPOB levels, we anticipate a substantial boost to overall growth realization as those sites keep scaling up. FY ’26 was a year of transformation for the group. And the early traction at our new facilities makes us confident that we can sustain, and in time potentially exceed, the Y-o-Y growth delivered this year, carrying that trajectory into the next fiscal year. Thank you. I will now hand things over to Mr. Pankaj Prabhakar, Group CFO, who will give his management commentary on the financials.
Good afternoon, everyone. I'm happy to report that Yatharth Hospitals turned in a strong performance in quarter four of financial year 2026, bringing the year to a robust close. In the quarter, revenue came in at INR3,416 million, which works out to 47% growth year-over-year and 6% quarter-over-quarter. For financial year ’26, the company posted revenue of INR12,072 million, a 36% increase year-over-year. This performance was fueled by sustained momentum at our existing hospitals, together with a growing contribution from our newly operational facilities. Our established hospitals kept up a healthy growth trajectory in the quarter and across the year, backed by higher occupancies, strong patient footfalls, growing surgical volume and a rising contribution from super specialty treatments. Occupancy for the network was 71% in quarter four of financial year ’26, while occupancy for financial year ’26 was 68%. During the quarter, our Noida Hospital ran at 86%, Greater Noida at 76%, Noida Extension at 61%, Jhansi-Orchha at 86% and Greater Faridabad at 69%. Our ARPOB rose to INR33,282 in quarter four of FY ’26, up 5% year-over-year, while ARPOB for FY ’26 was INR33,124, up 7% year-over-year. Notably, in quarter four, our Noida Extension Hospital recorded its highest ever ARPOB of INR47,800, up 23% year-over-year.
Greater Noida Hospital came in at INR40,300, a 15% increase year-over-year, and our newer hospitals posted encouraging initial ARPOBs — New Delhi at roughly INR40,000, Faridabad Sector 20 at INR38,000, and Greater Faridabad at INR31,000 — which reflects continued improvement in mix. Turning to profitability, we hit our highest quarterly EBITDA ever at INR799 million, a 37% rise year-over-year, with an EBITDA margin of 23.4%. For FY ’26, EBITDA was INR2,921 million, with margins of 24.2%. If you adjust for the initial ramp-up losses at our new hospitals, the adjusted EBITDA margin stays strong — 30.4% in quarter four and 28.5% for FY ’26 — which reflects operating leverage and an improved mix. Profit after tax in quarter four FY ’26 was INR447 million, up 15% year-over-year, and FY ’26 PAT came to INR1,703 million, a 30% increase year-over-year. This profitability improvement was driven by strong revenue growth, operating efficiencies, better realizations, and the scaling up of newer hospitals. Our balance sheet is still robust, backed by strong cash generation and disciplined capital deployment. Over the year, pre-tax operating cash flows were INR2,866 million, with a cash conversion ratio of 98%, which reflects a significant gain in working capital efficiency. We closed the year with a healthy total cash position of INR3,931 million and a net cash position of INR1,160 million, giving us ample financial flexibility to pursue growth opportunities while we keep investing in infrastructure, technology, and clinical excellence.
Given a solid execution framework, better trends in occupancy, the addition of new facilities such as Agra coming up to speed, plus ongoing emphasis on operating efficiencies and growing specialties, we are confident about maintaining robust growth momentum over upcoming quarters. Thanks for listening. I’d now like to pass the call to the moderator for the question-and-answer session. Thank you.
Thank you so much, sir. Ladies and gentlemen, we're now starting the question-and-answer portion. <<operator_script>> Our first question comes from Ashutosh Adsare of Universal Sompo, who is on the line. Please proceed.
Okay, hello there. Can you hear me clearly?
Yes.
Yes.
Good morning, everyone, and thank you for the chance to speak. I’d like to get some clarity on the new hospitals — Agra, Model Town, Faridabad, Jhansi, and Gurugram as well. Could you walk us through the operational parameters and let us know how these newer facilities are performing? Also, on Jhansi specifically, what’s the situation there — what occupancy level is it running at right now? You mentioned 86%. Has the ARPOB gone up at that hospital? Because we’ve been noticing that ARPOB at Jhansi specifically hadn’t been up to the mark, or below where the company overall sits. That’s the first point. My second question concerns interest cost. We’ve observed a fairly large sequential increase in interest. So I just want to understand where your debt stands, and what the debt position is likely to look like in the year ahead?
Okay, so on the occupancy side, as you've been mentioning, our new hospitals—mainly the ones we've opened in Delhi, Faridabad Sector 20, and Agra—give us plenty of headroom when it comes to occupancy levels. Right now in Model Town, that's Delhi, we're at a 32% occupancy level, with a census capacity of 100 beds, though our bed capacity in Delhi is 300 beds. In the same way, speaking of Faridabad, the newer hospital, we currently have 52% occupancy on 100 beds, with a capacity there of 400 beds. In Agra, our current occupancy level stands at 52%, with a census bed count of 110 and an overall capacity of 250 beds. So when it comes to overall bed expansion and capacity, we have sufficient headroom to grow along with the occupancy level. And as for Jhansi, Jhansi at present is running at roughly 85% occupancy on the 250-bed census level, with a bed capacity of around 305. So there too we have enough headroom for full network occupancy as well as expansions.
On your question about how Jhansi affects ARPOB for the group overall: Jhansi's ARPOB does sit below the group average, but at the group level the impact isn't significant, since Jhansi's share of our revenue pie chart is quite small. So if you look at it, in fact — as we said in the commentary — ARPOB has actually been rising at a strong pace for our mature hospitals too, Noida Extension and Greater Noida, which have reached above INR43,000 and INR48,000 where ARPOB is concerned.
Regarding the interest expense — that was your third question. As we’re aware, we’ve put money into Agra. So we took out a certain loan in order to finance the Agra unit. That’s the primary reason there’s an increase in interest cost, which is what you’re asking about.
Now regarding where debt stands, our debt today sits at around INR230 crores. That said, moving ahead there will still be some debt, though we'll also be producing robust internal accruals along with strong cash flow conversion cycles, and those will drive internal accruals even higher down the line. So yes, going forward we will take on some debt as well. But even looking at it today, on the net debt cash position, we stand — our net debt today is at INR116 crores. So our net debt today is — the net cash position is INR115 crores.
And what levers do you see for pushing ARPOB higher from here?
When you consider our approach for the new hospitals — including the Delhi hospital and the Sector 20 Faridabad Hospital — those two only recently opened, yet even so they're showing an initial ARPOB above INR40,000. So as volumes and cases grow and specialties mature at these facilities, they'll serve as meaningful ARPOB drivers for additional growth. Regarding the Gurugram Hospital, we anticipate ARPOB there will be above INR50,000. That's mainly for three reasons. The first is the optimized case mix at that location; having international patients, plus higher pricing on private insurance and cash tariffs in the Gurugram region, will also substantially support our ARPOB growth drivers. And we've been consistently expanding the share of private insurance as well as cash and international patients, which this year has also produced a Y-o-Y increase of roughly 7% where ARPOB is concerned; looking ahead, that growth ought to be near 10% in the years to come.
And to add to that, we're also enhancing the specialty mix at every one of our hospitals. So although Noida Extension carries a big proportion of super specialty hospitals, we're likewise raising the proportion of super specialty cases at all the remaining hospitals, and that too is going to help lift the ARPOB.
All right, that covers what I had. Should anything else come up, I’ll get back in the queue.
Thanks. Our next question comes from Satyam Kumar at JM Group Financial Family Office. Go right ahead.
I appreciate the chance to speak. Can you hear me okay?
Yes.
Yes, sir.
Yeah, so I’ve got a couple of questions. The first one is this: could you walk us through the steps the company has taken since listing to strengthen corporate governance? And how do you see things going forward — what steps would the company take? Or is it more or less settled now? So the first question concerns overall corporate governance: how do you see it evolving further?
For us, corporate governance has been a top priority for management ever since our listing. Looking at our journey since then, and particularly over the past 18 months, we've taken several steps to strengthen it further. It begins with bringing on a top-six audit firm, BDO International — MSKA & Associates. They were named the company's statutory auditor a couple of quarters ago. In fact, this year's financial results were the first ones produced with BDO International serving as statutory auditor. The second step involved appointing Mr. Ramesh Krishnan as an Independent Director. So our Board has been expanded, and we've brought on a strong independent director. Today we have him and his expertise. He is a seasoned healthcare professional who has worked across various organizations and is helping strengthen our corporate governance at the Board level. Another step we took was appointing Deloitte as internal auditor. That too took place over the course of the last year, and it has further helped us fast track our financial systems and processes and strengthen governance mechanisms with Deloitte's help.
So those are a handful of the steps we’ve taken when it comes to bettering and fortifying our corporate governance.
Also, looking ahead, just to give some qualitative color on the business, we're bringing in a couple of really important roles on the operations front — to handle our medical operations and also on the quality side of things.
Got it, thanks for the question. And I have another one that's more about expansion. You mentioned the company's goal of reaching 5,000 beds over the next three years. So first, I want to say I really like how you've grown your portfolio and the types of acquisitions you've made. Looking ahead, do you see yourselves acquiring those hospitals, or will you also build hospitals from scratch? Any vision you'd be willing to share? I know it's a stretch, but anything on your mind? And will that push debt levels up as well? And how would it affect — profitability is the second thing, but how are you planning to expand, basically?
Now regarding the 5,000-bed goal across the coming three years — 3,200 beds have already been announced, on top of the 2,500 beds we operate today. The Noida extension, Greater Noida, and the upcoming Gurugram Hospital together make up that 3,200. On hitting 5,000 beds within the next three years, first, we believe we could get there even sooner than three years. In the past we have consistently exceeded our bed capacity targets, and that could well happen again going forward. On the split among greenfield, brownfield, and acquisitions for these upcoming beds, we think roughly 70% will come mostly through acquisitions and 30% through greenfield additions. And these will mainly be in cities we understand and know very well. We haven't simply gone to any outside area just because there's a hospital to acquire. We have been selectively choosing an asset and then moving forward on an asset because geography matters a lot to us. There's a reason all the recent acquisitions have done very well — they have been strategically located in the well-established markets of NCR, bigger cities of North India, capital cities of the states, and Uttar Pradesh, Haryana, Punjab; these have major cities and metro cities where we would also like to be going forward.
On the capex plan for this bed expansion, we believe our cash position today is solid. There's also still headroom when it comes to certain debt. And as we said, given the high cash conversion percentage, we'd be generating greater internal accruals going forward. So we're well positioned to fund this capex. There's no plan to raise any funds going forward for this specific 5,000 bed capacity.
I just have a quick follow-up on that. As you mentioned, the geography matters to you, and the 70% could also come via acquisitions. So I wanted to specifically understand what Yatharth Hospital does differently. Do we have an M&A team, or how do we go about it so that we end up with such strong acquisitions? And just on the operational side, I'd like to understand how the company differs from any other company when it comes to acquisitions. Because I believe we are at the forefront of acquisition. So operationally, if you could share, what is it that we do differently?
So I believe we have a solid team, and Ashutosh, who is here with us today, leads it. He's in charge of group M&A strategy. As a result, he has played a key role in a number of the deals we've completed lately. We also have a group that is always scanning for assets, but beyond that, we have very straightforward, clearly defined criteria when it comes to acquisitions. It's not as though we have to draft criteria for each asset we come across. To us, the capex per bed has to be sensible. To us, it matters that the geography is large enough and that it's a healthcare market with a proven track record, including within the micro market. And the cluster approach we've adopted has been key. If you look, we began with a single hospital in Noida, and now we have three hospitals there. We began with a single hospital in Faridabad, and we have two there. In the same way, we have just seeded a new cluster in Gurugram with a hospital. But every one of these clusters — and again, the UP cluster we run, which includes the Agra and the Jhansi-Orchha Hospital, holds potential for a cluster-based approach, which really helps us ease into acquisitions while identifying the clusters we want to operate in, and then we pick the assets that are available in those clusters.
Got it. I appreciate you taking the time to answer my question so patiently. If anything else comes up, I'll rejoin the queue.
Thanks. We’ll take the next question from Akshat Mehta at Seven Rivers Holding. Your line is open.
Hi there. Can you hear me okay, sir?
Sir, could you please pick up your handset? We’re getting some static. Yes, go ahead.
Yeah. So, first thing I want to ask about is how we should understand that big jump in ARPOB at Noida Extension, Greater Noida — before it was 8% and now it's 15% <<inaudible>>. Is that purely down to a case mix jump? Or is something else driving that increase?
There's more of a jump on OPD, and that carried over into IPD. And on top of that, yes — as we said in our earlier commentary, these super specialties aren't mature yet. So I think quarter-on-quarter they are maturing, with new lines of treatment being added within the super specialty. So I think those are the factors that have improved ARPOB significantly.
We're also seeing a rising number of international patients at Greater Noida and Noida Extension Hospital. The share of international patients, particularly at those two hospitals, has gone up considerably, and that has contributed heavily — it has even exceeded what we expected for ARPOB when it comes to growth at these two hospitals. And especially now that the new Noida Airport is starting, with international flights taking off from there very soon. The ecosystem around international tourism and medical tourism across the Noida zone is really on an upward trend. And we believe both of these two hospitals are benefiting from that industry trend.
This is just a follow-up question. Could you tell us what the oncology share in Noida Extension stands at right now? Earlier it was 19%, 20%.
Right now it's roughly 30% at Noida Extension Hospital, as far as that facility goes. So oncology's share is climbing toward — I'd put it near 30%, up from 20%. The main driver is growth in oncology's key segments, meaning surgical oncology and bone marrow transplant. We've been doing a very strong volume of bone marrow transplants, and that adds to it as well. We've also brought in a new oncology doctor team at Noida Extension Hospital, and that is helping us push this volume further.
My second question concerns revenue and margin, sir. How ought we to view these in FY ’27? Since we have made an acquisition that will come in April 2027. Every acquisition we finished in ’26 is simply going to ramp up in ’27. So, in what way should we view the margins and revenue?
When it comes to margins, we've consistently said that for the full year at a consolidated level, our guidance has remained in the neighborhood of 24% to 25%. And we've been delivering on that. Looking ahead, we also don't anticipate any deviation from that margin guidance. Yes, a new hospital may be coming in ’27, but three new hospitals already came up in ’26 as well. We added roughly 1,000 beds of capacity during the financial year ’26. Even with that, we've held a steady margin above 24% across the entire year. So we believe that, in fact, starting this financial year, EBITDA margins — next financial year, EBITDA margins ought to actually be better. A similar picture should emerge where our revenue growth is concerned too. Over this full financial year, we grew revenue Y-o-Y by somewhere close to 36%. We believe that in ’27, this — we would exceed that 36% Y-o-Y revenue growth.
Just a quick follow-up on that, sir. Roughly when should we expect the New Delhi and Faridabad hospitals to reach breakeven?
Honestly, both of these hospitals are performing fantastically well. To be completely candid, results have exceeded what we expected. So the Faridabad unit, Sector 20, is likely — that hospital would probably be the first in our growth to obviously reach breakeven within a month, or at 10 or 11 months at the latest. As for Delhi, it will probably take close to around 14 to 15 months.
I think if you put those two hospitals together, what you'll see in FY ’27 H2 is that both of them reach EBITDA breakeven.
All right, let me squeeze in one final question here. I'm just trying to get a handle on where things stand with our brownfield additions in terms of the cycle — have we actually broken ground, or what's the exact status? And what's the reason it seems to be taking — has it been pushed to the back burner given all the new beds that are coming in through those brownfield additions? Or where exactly does it sit?
So we've commissioned the brownfield expansion plans for the Greater Noida Hospitals. The structural drawings have just been finalized, and the basic construction work has also begun. As for Noida Extension, similar phases apply there. It's not that we deliberately slowed it down. It's just that when we were adding new beds in other parts of NCR, that became the first priority. However, the legal formalities and everything else have now been completed for both of these hospitals. And we feel that's at the right time, because both hospitals still have some occupancy ramp-up yet to be seen. So by the time we will have this brownfield capacity with us is when we will actually be requiring them. So as far as those two brownfield hospitals' plans are concerned, it's pretty much on track.
All right, sir, thank you. I’ll rejoin the queue.
Thanks. Our next question comes from Nilay Parekh of Perpetuity Ventures LLP. Please go ahead.
Hi, everyone. I’ve got two questions. First, could you give me the ARPOB along with the occupancy percentage across all the units? And second, what’s the outlook for debtor days by the end of FY ’27? Thank you.
Okay, so for the quarter, blended occupancy overall came in at 71%, and with the new hospital coming on line there's still sufficient headroom, which was also covered in the earlier question. Now, Model Town Hospital, opened during this financial year, sits at 32% occupancy on a census bed count of 100, out of a capacity of 300 beds. For the new Faridabad facility, occupancy stands at 52%, with census beds of 100 and a capacity of 400 beds. Agra is at 52% occupancy, with a census of 110 and a capacity of 250 beds. Greater Noida comes in at 76% occupancy, census of 330, capacity of 400 beds, with additional expansion as described in the brownfield expansion. At Noida one, occupancy is 86%, census of 215, capacity of 250 beds. Noida Extension shows 61% occupancy, census of 390 beds, total capacity of 450 beds, with more capacity to be added through the brownfield project. Jhansi-Orchha is at 86% occupancy, census beds of 250, full capacity of 305 beds, and Greater Faridabad — the old Faridabad hospital — has 69% occupancy, with census beds of 150 and a capacity of 200 beds.
Occupancy overall came in at roughly 71% for Q4, and for the full year it ended at 68% in total.
Thanks. And my second question was about the debtor days outlook by the close of FY ’27.
Yes, sir, as we mentioned before, in FY 2025 we recorded debtor days of 124. And in this year, that is financial 2026, our debtor days came in at 112. That came from driving process efficiencies and controls, along with cutting the time to dispatch the beds and upload through outsourcing that work. Also, for FY ’27, the outlook is around 90 to 95 days. What we’re targeting is 90 to 95 days for FY 2027.
Alright, thanks a lot.
Thanks.
Thanks. Our next question comes from Dikshant Gupta at Geojit PMS <<inaudible>>. Go ahead, please.
Morning, and thanks. Yeah, hi. I’ve just got the one question. Could you tell me what the payer mix looks like for FY ’26 compared with FY ’25?
The payer mix is pretty much unchanged—just a 2% to 3% decline. Government payers sit at close to 35%, and cash plus TPA makes up the rest. As we said in our earlier question, though, work is underway to bring that down to closer to 25% over probably the next two financial years.
So, yeah, you figure over the next 2 financial years, it’s going to…
I’ll add — sorry, let me just bring you in on this effort — that if you examine any of our new hospitals, the share of government business is very, very low. That’s something we’re keeping control over. And with the existing ones as well, we’re being very selective in what we choose.
So once Sector 20 Faridabad is up and running, Model Town hospital has opened, and the Gurugram facility goes live over the next few quarters — in those hospitals, we don't see government business exceeding 10%, 12% within 2 years. That's where the total share of government business will decline as these newer hospitals grow their contribution to revenue. We can pull this off because today, in those cities, we're being joined by the most reputed, clinically star doctors, who bring with them a huge clientage of private insurance and self-pay patients, plus international patients — and we can now serve them at large scale since we have the treatments international patients need, something we didn't have 4, 5 years back. That's how we're so confident, and it's already showing in the numbers from our new hospitals, that 2 years down the line, government business should be around 25%.
All right, thanks a lot. And regarding that 35% government mix you mentioned — is CGHS the majority of it?
There are essentially 3 schemes involved: CGHS, ECHS, and ESI. The rates across all of them are, more or less, CGHS rates.
It differs from one hospital to another, and honestly, it's hard to give an overall figure. It has — at some hospitals, the CGHS share is bigger. At one particular hospital, situated right opposite Asia's largest ECHS society, ECHS patients account for a larger portion. So, by and large, it's on a comparable footing.
Right. But doesn't that mean the majority of those rates are tied to CGHS?
Correct.
Yes.
Okay. Okay. And here's my final question. With the West Asia crisis going on, are you noticing any decline in international patients during Q1 FY ’27?
Okay. So overall, what we observed is that over the past 3, 4 months, whatever took place, there was a downturn throughout the industry. But our view is that a few of those — especially for India, since Bangladesh was shut, Afghanistan was shut, and the Middle East has been disrupted. Yet we believe that in the coming quarter, these issues will be resolved, and we will gain substantially. Our efforts are heavily invested in this. As a matter of fact, we are very strongly focused on the African market. We have dispatched our very senior resources into those countries. 2, 3 medical centers are being operated, and we will start very soon. A few of the initiatives that we undertook in the last financial year, I think they are maturing. So, we are receiving a substantial inflow from those regions. So, yes, we feel that the next quarter, the coming quarter, I think the numbers will be much better.
Alright. Thanks a lot, and best of luck.
Thanks. Our following question comes from Dhaval Sangoi at Canara HSBC Life. The line is yours — go ahead.
Yeah. Hi there. Good morning. Appreciate you taking my question. So, when it comes to the CGHS rate benefit, could you put a number on it — the one we would have booked in FY ’26 and Q4?
Right, so yes — with the government's revised guidelines that came out in December, there's roughly a 5% upside across our business overall.
Beginning in December, looking at it month by month, we've gained 5% on total revenue where the rate increases are involved, and over 3% of that has dropped through to EBITDA as well, as far as that goes.
All right, so it's fair to say that, on a base of roughly INR1,200-odd crores, the benefit in overall revenues for FY ’27 would perhaps be INR60 crores to INR70 crores?
No. So that began in December, correct? So the actual effect you'll observe would come from this year. So I think mainly from Q3 and Q4 — the second half of Q3 and Q4 is largely where you'd see that 5% increase.
So the full impact of that 5% only landed in Q4 of FY 2026. The complete effect of the 5% will show up in the next financial year, which is FY 2027.
Alright. For my second question, on the oncology side — some of our peers have reported some disruption when it comes to the chemotherapy drugs, where there's been a bit of price control and some conflict. So have we seen any impact at all when it comes to volumes or numbers?
Yes, so there has been some effect, though from our perspective it isn’t a major one. At the group level, oncology accounts for 10% of total revenue. What we’ve now measured is that certain oncology drugs had their pricing capped. As far as that effect goes, within that 10% oncology revenue, we’re seeing an impact of roughly 20%-odd to 30% on pricing inside that 10% oncology share. So it isn’t that we’ve halted those drugs entirely. We also recognize that substitutes for these drugs aren’t all that straightforward and aren’t so readily available. So yes, we have been observing a marginal impact. Even so, we believe that going forward this year — because of the CGHS rate revision — the oncology revenue pie will still keep growing for us. And still, for oncology, if you look, some of our hospitals have recently launched oncology, and oncology machines such as radiation oncology are still set to begin soon as far as sector Faridabad 20 is concerned, and as far as Model Town, New Delhi is concerned.
For us, oncology revenue is still going to keep growing. That said, we have seen a very marginal impact from the new government policy that has come up.
Also, to build on what Mr. Yatharth said, we haven't halted that. A number of patients are getting their medicines from CGHS and ECHS dispensaries. At the same time, we're running a parallel effort to reduce the impact. There are additional oncology streams as well — radiation oncology, surgical oncology, and bone marrow transplant — and we're putting more focus there.
Alright, thank you.
Thanks. <<operator_script>> Next up, we have a question from Surya Narayan Nayak at Sunidhi Securities, calling in. The line is yours — go ahead.
Yeah. Hi. Hello, everyone. Can you hear me?
Yes, sir.
Yes.
Okay, I have a couple of questions to ask. When it comes to the Gurugram hospital acquisition, what sort of specialty mix are you aiming for at that facility?
So, Gurugram — look, if you look at any of our hospitals, it's really all about the tertiary and quaternary care services that we'd be providing right there in Gurugram itself, because we think Gurugram is a highly competitive market too, but at the same time, it comes with a really large potential catchment area, right? So we need to have a facility in Gurugram that offers strong tertiary and quaternary care.
All right, and can you go into more detail about the timeline you're aiming for to get that Gurugram facility to breakeven? Also, it would help to know what mix you expect, both when it comes to specialty and from the payer mix angle.
So I think Gurugram will be up in 13 to 15 months, right? And on the mix side, there will definitely be more on self-payer and insurance business. As we said just now, that's — we want a bit of control over the government business.
Along those same lines, the expectation for reaching breakeven would be roughly 15 months starting when it becomes operational. We feel quite confident that, as far as the brand-new financial year is concerned, it ought to be recorded on our books from day one.
Right, that’s everything, sir. Thanks.
Thanks. Our next question comes from Archit Agrawal, who is on the line from Steptrade Capital. Go ahead, please. Mr. Archit Agrawal, please proceed with your questions. Sir, I have unmuted your line. Since there is no response, we will move on to the next question, which comes from Vidhi Shah on the line from CR Kothari & Sons. Please go ahead.
Good morning, sir. Sir, I'd like to ask, how much are we currently losing from the new hospitals? And when do we expect the Agra hospital to break even?
Looking at the whole pie at Model Town, New Delhi, we have a loss — an EBITDA loss of INR21 crores. Likewise, the new Faridabad hospital, which launched this year, carries an EBITDA loss of INR9 crores. Taken together, the EBITDA drag comes to roughly 2% of the total pie in terms of net losses. But as we've said about this, in H1, at about 12 months to 15 months, we'll be able to reach breakeven on EBITDA, so to speak, to kind of support <<inaudible>> across the whole thing.
Yeah. As for Agra, Agra on its own accounts for roughly 18%.
So this hospital is profitable, and it's adding to our EBITDA margin — it already has an EBITDA margin of 18%. So when we bought the hospital, it was already at breakeven. So it isn't a drag on EBITDA for us.
Okay, that's great. And sir, do you have any guidance on revenue and margin for FY ’27-’28?
As we've already mentioned, when it comes to both EBITDA and the top line, we will exceed the growth we've demonstrated this year.
Alright, thank you, sir.
Thanks. Our next question comes from Rishikesh Bhoi, who is calling in from Purnartha Investment Advisors. Rishikesh, the floor is yours.
Yeah. Morning, everyone. So I’ve got one follow-up question, and it relates to our brownfield expansion. What’s the cost per bed for the Greater Noida and Noida Extension expansion? Is there any cost escalation later on because of uncertainty in current energy prices?
I think the cost for the brownfield expansion at both of these two hospitals comes to roughly INR75 lakhs of capex per bed. That's because the land has already been acquired, so it isn't included. And also since certain machines and certain items are already present in the towers that are already running. So that's the reason the CapEx per bed would be about INR75 lakhs per bed, and we don't expect any escalation of the cost there.
All right, thanks.
Thanks. Our following question comes from Satyam Kumar at JM Group Family Office, on the line. Please proceed.
Thank you for taking my question. Sir, I'd just like to get an update on the income tax matter — where do things stand at the moment?
The income tax matter is nearly at the last stage of being settled. Also, if you look at the order notes in this fiscal year's balance sheet, some years have been closed, and for certain years an order has been received. That said, the company has examined it and doesn't foresee any significant financial liability or any substantial cost on that front. To get the full case order issued, our sense is that the entire matter should be resolved sometime before quarter two of this financial year ends. And as things stand today, there is no financial liability or any impact on our operations or any financial operations. Also, no FDs or any assets have been provisionally blocked or provided for. Everything is available for the company to use as per our patients.
Got it. And one final item. Sir, do the margins on procedures carried out under the various government schemes differ from one another — I mean the margin profile — is that the case?
Now, when you consider CGHS, ECHS and ESI, the margin picture is broadly comparable across those three schemes, since the pricing works out the same. All of them operate on CGHS rates. When it comes to Ayushman, though, that's where the margin profile is different. It generally runs considerably lower. That said, Ayushman is one we — yeah.
No, no, sir. What I was really after is how margins differ across the various procedures — for instance, does a cardiac procedure carry the same margin profile as neurology or nephrology under a government scheme? So under one and the same government scheme, do margins vary from procedure to procedure? Is that so? And does that mean we concentrate on performing procedures with high margins within the government scheme? Is that how it works? I just wanted to — and those are all the questions I have.
Yes, margins really do differ quite a bit inside the government scheme too. What procedures you're running makes a difference. For surgical procedures, the margin profile looks different. With conservative treatment, margins are very different there, correct? And what was the second question again?
Take oncology, for instance — margins there are usually stronger than what you'd see from, say, other procedures under the government scheme, and cardiac procedures are the same way. So yes, even within the government side of things, we do at times deliberately concentrate on specialties that carry higher margins.
But again, that hinges on—let's say we're opening a hospital in specific areas, and we've got bed capacity, so maybe you need those numbers to fill the beds. So, I mean, that's a process, right? So, as you mature, as your occupancy fills up, you try to become a bit more selective, with more controls over the business.
Got it. And sir, what was ARPOB for the Agra hospital?
Agra is posting an ARPOB of roughly about INR26,000 to INR27,000, and for that region, that's pretty solid.
Understood. Noted, sir. I appreciate it. I'm grateful that you took the time to answer my question so patiently. Thank you.
Thanks. Our next question comes from Akshat Mehta at Seven Rivers Holding. Your line is open.
I just need one clarification — when you mentioned Agra ARPOB, what did you mean by that?
The figure is INR26,000.
INR26,000. Okay. My other question was on the overall — I just wanted to understand on the CGHS benefit where you said that 5% on the revenue front and 3% on the EBITDA front, right? A couple of calls back in FY ’27, we had estimated that the revenue impact will be 2.5%, and it will be 1.75% on the EBITDA front. Has the benefit kind of gone up? Or is this — I mean, because 5% and 3% are for Q3 and Q4, we should accordingly take it for the full year.
So the benefit, whenever it comes to the CGHS piece, has stayed comparable across the whole business. When you look only at the government business, the CGHS benefit, measured as that percentage, does tend to come out differently. So that's likely the reason the numbers can vary.
Regarding those figures you mentioned, 4.5% and 1.7% — the 4.5% applied to the entire quarter, and that's the same figure we're citing at present as well. The 1.7% came in the quarter when the scheme — when the price increase went into effect. As a result, we didn't receive the benefit across the whole quarter. That's the reason the benefit for that quarter stood at 1.7%.
And the benefit came in stages as well. Some schemes rolled out the rate revisions first. Others needed more time. So at this point, the rate revision has been fully implemented across CGHS, ECHS and ESI. That's where, in our overall calculation, we feel it should contribute 5% to our overall revenue.
Alright, and sir, my next question: if you look at the balance sheet, there's been a large increase in other assets, financial assets, and other current assets. What's the reason for that?
So, a fixed deposit is involved. There's a presentation of the books of accounts in accordance with Ind AS. These FDs sit within the other financial results. That is the sole reason you're seeing an upside in that figure relative to last year.
So during the final week of the financial year, we hold solid collections from the various payers. As a result, we've placed those funds in these FDs on a temporary basis, which lets us earn the best returns on them.
Alright. Alright. Thanks.
Thanks. Our following question comes from Gopal Bhatt at Baroda BNP Paribas AMC, who is on the line. Kindly proceed.
Hello there. Hi. Thanks for the question. Yeah, I just wanted to confirm something. I was looking at the strategy slide in the deck, and I notice you've placed emphasis on a cluster-based approach in Delhi. I just wanted to verify that, given — how do you see competitive dynamics across the overall market, considering you also have much bigger players operating there? And related to that, what sets Yatharth's strategy apart from other peers?
On the cluster-based approach — we do have a tendency to become the biggest player in the regions where our core operations sit. So much like what took place in Noida, we've already demonstrated that with three hospitals. Those are, in a sense, separate micro markets inside one city. That's exactly what we're doing with Faridabad. The two hospitals in Faridabad and the three in Noida each sit roughly 20 kilometers apart from one another. So we end up serving distinct micro markets within that same city. That said, it gives us an edge as far as building the brand within that city goes. So today, when we're working to bring star doctors on board in Faridabad, having two hospitals on opposite sides of town, each serving separate micro markets in that city, helps us get that talent in. Within the Delhi region as well, within the Gurugram region, this is the same approach we'll take. What makes it a bit different is that we pinpoint micro markets that are, in a sense, unmet within NCR and the regions beyond — there are still plenty of areas, which a city might have plenty of hospitals in.
Yet inside those cities, the remaining zones are still emerging zones, and those are growing with population, with high-rise urban communities that we are pinpointing. And in a way, that assists us in entering those regions early and in building a larger brand within those cities. And it isn’t only hardcore NCR that we are considering. Our UP cluster, which began with the seed from Agra, still holds enormous potential. So too does Haryana beyond merely Gurugram. And we would be examining a considerably larger market throughout North India, and we believe assets exist that can be acquired. Some may not suit certain other players who might be seeking, let’s say, a larger parcel of land or a bigger size for a hospital. And at times, for us, that size might be acceptable. Some other players you mentioned might already be operating in those areas. But for us, it could represent a good entry into those areas. And these are the factors that have, in a way, helped us to make these acquisitions, and that is why we are quite confident of exceeding our target of 5,000 beds over the next years. I think we should get there much sooner.
All right. And sorry, sir — on the second part, or if I may just ask a follow-up: considering that Delhi NCR is fairly competitive, what sets our offerings apart from those of other players there?
Look, when it comes to Delhi NCR, healthcare offers an enormous opportunity. Places like Noida, Gurugram, Faridabad, and even Ghaziabad, along with other sections of Delhi, continue to see their populations expand at a tremendous rate. In fact, these areas are still — they remain nowhere near saturation. That means there is ample room for high-quality hospitals and for top-tier clinical talent to set up shop. One thing that has somewhat worked in our favor in the past is that we have always been a very doctor-friendly organization. In that way, we have managed to draw clinical talent thanks to that approach. We have generally not adopted the model of P&L-driven, corporate-led organizations in which clinicians receive targets to hit certain numbers. We have consistently, in a way, offered a comfortable setting for clinical talent to come aboard. And that is, in a sense, the reputation we have built, and that explains why many other clinical talents today wish to join us as we move into new areas. Where our infrastructure is concerned, it still stands on par with every other player in the region. With regard to some of our newer hospitals, we are attempting to build a somewhat more boutique hospital setting, since these days, when patients go to big massive hospitals, they sometimes feel lost.
But by taking a far more patient-focused approach, using the same clinical expertise and offering a much more tailored, boutique-style hospital experience, that's where we believe we're bridging the gap in metro cities and in regions where larger competitors may sit 10 or 20 minutes away from us. Still, this is the kind of gap we're also attempting to close in the capital and the metro cities where we operate.
All right, thanks very much.
Thanks. That will have to be the final question for today, everyone. At this point I’ll pass the conference to Mr. Yatharth Tyagi, who has some closing remarks. Thanks, and the floor is yours, sir.
Thanks, everybody. I appreciate all of you joining the conference call covering this financial year of ’26, and we’re grateful for your questions. Thank you.
<<operator_signoff>>
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Yatharth Hospital & Trauma Care Services Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Yatharth Hospital & Trauma Care Services Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.